Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216049 | 0.97 | MAPK1 (0.35) | MAPK1CRHR1ACHEBCHEHRH4 | |
| SCHEMBL7220024 | 0.87 | MAPK1 (0.35) | MAPK1CRHR1ACHEBCHEHRH4 | |
| SCHEMBL7214399 | 0.86 | CRHR1 (0.42) | CRHR1ACHEALDH1A1 | |
| SCHEMBL7213699 | 0.84 | MAPK1 (0.36) | MAPK1CRHR1ACHEBCHEHRH4 | |
| SCHEMBL7220786 | 0.83 | CRHR1 (0.36) | CRHR1NPSR1 | |
| SCHEMBL7219612 | 0.80 | CRHR1 (0.37) | MAPK1CRHR1CYP2C9CYP2C19NPSR1 | |
| SCHEMBL7216177 | 0.80 | CYP2C9 (0.33) | CYP2C9CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL7213919 | 0.79 | CRHR1 (0.49) | CRHR1ALDH1A1 | |
| SCHEMBL7220093 | 0.79 | CYP2C9 (0.34) | CRHR1CYP2C9CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL7216123 | 0.79 | CRHR1 (0.34) | MAPK1CRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | claimed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | claimed |
| US-6589958-B1 | Treatment of psychiatric disorders and neurological diseases including affective disorder, anxiety, stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | MAPK1 649/4885CRHR1 1/4885ACHE 4735/4885 |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | MAPK1 649/4885CRHR1 1/4885ACHE 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.